Qihuang Zhengqi granules

Qihuang Zhengqi granules is an investigational traditional Chinese medicine (TCM) Class 1.1 innovative herbal granule formulation being developed by Jiangsu Kanion Pharmaceutical (Kangyuan Pharmaceutical). Developed under the guidance of traditional Chinese medicine theory, it is a clinically derived formula designed to benefit qi, nourish blood, and support vital qi. It is being evaluated for the treatment of cancer-related fatigue. In preclinical studies, Qihuang Zhengqi granules demonstrated significant therapeutic effects against cancer-related fatigue induced by murine Lewis Lung Carcinoma transplant tumors and paclitaxel-treated breast cancer models. In July 2026, the National Medical Products Administration (NMPA) of China approved the initiation of clinical trials for this formulation.